SPX Technologies Appoints Daniel Whitman as New General Counsel, Enhancing Leadership Team
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy SPXC?
Source: Globenewswire
- Leadership Enhancement: SPX Technologies appointed Daniel Whitman as Vice President, General Counsel & Secretary on January 5, 2026, aiming to leverage his extensive experience in the industrial technology sector to drive the company's growth and operational initiatives.
- Legal Expertise: With over 20 years at Parker Hannifin, where he served as Vice President responsible for commercial and operational support, Whitman is expected to provide robust legal guidance to SPX.
- Rich International Experience: Having led Parker Hannifin's legal team in Europe, the Middle East, and Africa during his expatriate assignment in Switzerland, Whitman brings valuable insights for SPX's international business expansion.
- Outstanding Educational Background: Whitman holds a Juris Doctor degree from the University of Akron and a bachelor's degree in mechanical engineering from Purdue University, providing a diverse perspective that combines legal and engineering expertise for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPXC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPXC
Wall Street analysts forecast SPXC stock price to fall
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 230.920
Low
210.00
Averages
226.88
High
244.00
Current: 230.920
Low
210.00
Averages
226.88
High
244.00
About SPXC
SPX Technologies, Inc. is a diversified, global supplier of engineered products and technologies in the heating, ventilation, and air conditioning (HVAC) and detection and measurement markets. Its segments include HVAC and Detection and Measurement. The HVAC segment engineers, designs, manufactures, installs and services cooling products and engineered air movement and handling solutions for the HVAC industrial, commercial, data center, and power generation markets, as well as heating and ventilation products for the residential, industrial, and commercial markets. The distribution channels for the segment’s products are direct to customers, independent manufacturing representatives, third-party distributors, and retailers. The Detection and Measurement segment engineers, designs, manufactures, services, and installs underground pipe and cable locators, inspection and rehabilitation equipment, robotic systems, transportation systems, communication technologies, and aids to navigation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Coinbase Rating Maintained: Bernstein reiterates Coinbase as outperform, noting that despite Q4 revenue missing estimates by 3% and a 28% drop in adjusted EPS to $0.66, the stock remains undervalued, indicating long-term optimism.
- Instacart's Strong Performance: Barclays maintains an overweight rating on Instacart, highlighting its rare beat-and-raise earnings report in the internet earnings cycle, suggesting a unique advantage in a competitive market that may attract more investor interest.
- Airbnb Upgraded to Buy: Deutsche Bank upgrades Airbnb from hold to buy, stating that while it faces AI disruption risks, its unique supply chain offers more insulation compared to peers, which is likely to draw more investor attention.
- CrowdStrike's Attractive Valuation: HSBC upgrades CrowdStrike from hold to buy, citing attractive current valuation and projecting a non-GAAP EPS CAGR of 38.3% over FY26-29, indicating strong growth potential.
See More
SPX TECHNOLOGIES INC: BOFA GLOBAL RESEARCH UPGRADES TO BUY FROM NEUTRAL; INCREASES PRICE TARGET TO $280 FROM $240
- Global Research Initiative: A new initiative has been launched to buy from neutral sources, aiming to enhance global research capabilities.
- Price Increase Announcement: The objective price has been raised to $280 from the previous $240, reflecting the increased costs associated with the initiative.
See More
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
- Halozyme Financial Performance: Halozyme's Q3 revenue increased by 22% year-over-year to $354 million, with earnings per share (EPS) soaring 36% to $1.43, demonstrating its strong market position in drug delivery systems.
- Catalyst Growth Potential: Catalyst achieved a remarkable 249% revenue growth leading up to 2024, with Q3 revenue rising 24% year-over-year to $436.3 million and EPS climbing 45.9% to $1.27, reflecting strong demand in rare disease treatments.
- Competitive Advantage: Both companies maintain low debt levels, with Halozyme reducing its long-term debt from $1.5 billion to $800 million, while Catalyst has no debt, providing them with greater flexibility for acquisitions and R&D investments.
- Optimistic Industry Outlook: The biotech sector rebounded in 2025, with the SPDR S&P Biotech ETF rising 27%, indicating a resurgence in market demand for innovative drugs, while both Halozyme and Catalyst are valued below the sector average, suggesting significant future growth potential.
See More
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
- Biotech Recovery: In 2025, the SPDR S&P Biotech ETF surged 27%, nearly doubling the S&P 500's 16% gain, indicating a robust recovery in the biotech sector, supported by lower interest rates facilitating debt financing.
- Halozyme's Strong Growth: Halozyme Therapeutics saw its stock rise over 25% in the past year, with Q3 revenue increasing 22% year-over-year to $354 million and EPS jumping 36% to $1.43, showcasing its competitive edge in drug delivery systems.
- Catalyst's Profitability: Catalyst Pharmaceuticals reported a staggering 249% revenue growth from 2021 to 2024, with a 24% year-over-year increase in revenue to $436.3 million and a 45.9% rise in EPS to $1.27 this year, reflecting strong market demand in rare disease treatments.
- Optimistic Future Outlook: Halozyme forecasts annual revenue of $1.3 billion to $1.375 billion for 2026, representing 28% to 35% growth, while Catalyst anticipates revenue of $565 million to $585 million, nearly a 17% increase, indicating promising growth potential for both companies.
See More
Stocks Rebound as Trump Halts Greenland Tariffs, Future Deal Framework Announced
- Market Rebound: Stocks rebounded following President Trump's announcement to halt tariffs on Greenland, reflecting a renewed optimism in the market that could restore investor confidence and stimulate economic activity.
- Future Deal Framework: The “framework” mentioned by Trump suggests potential future trade agreements, which may positively influence trade relations between the U.S. and other nations, thereby impacting global market dynamics.
- New Buying Opportunities: Google and Eli Lilly emerge as leaders in new buying opportunities, indicating sustained investor confidence in the technology and pharmaceutical sectors, which could drive stock prices higher.
- Improved Market Sentiment: Trump's statement not only alleviates concerns over trade tensions but may also create more investment opportunities for other companies, enhancing overall economic growth expectations.
See More
Trump Halts Greenland Tariffs, Stocks Rebound
- Market Rebound: Stocks rebounded as President Trump announced he would not proceed with tariffs on Greenland, indicating investor optimism about a potential future trade deal, which could stimulate economic recovery.
- New Investment Opportunities: Google and Eli Lilly emerged as leading new buys, reflecting investor confidence in the technology and pharmaceutical sectors, potentially driving stock prices higher.
- Trade Framework Established: Trump's mention of a 'framework' for future agreements lays the groundwork for subsequent trade negotiations, which may improve trade relations between the U.S. and other countries.
- Investor Sentiment Improvement: With reduced uncertainty surrounding tariff policies, investor sentiment has improved, likely leading to increased capital inflows into the stock market, thereby enhancing overall market performance.
See More
Latest Wall Street Rating Updates
- Coinbase Rating Maintained: Bernstein reiterates Coinbase as outperform, noting that despite Q4 revenue missing estimates by 3% and a 28% drop in adjusted EPS to $0.66, the stock remains undervalued, indicating long-term optimism.
- Instacart's Strong Performance: Barclays maintains an overweight rating on Instacart, highlighting its rare beat-and-raise earnings report in the internet earnings cycle, suggesting a unique advantage in a competitive market that may attract more investor interest.
- Airbnb Upgraded to Buy: Deutsche Bank upgrades Airbnb from hold to buy, stating that while it faces AI disruption risks, its unique supply chain offers more insulation compared to peers, which is likely to draw more investor attention.
- CrowdStrike's Attractive Valuation: HSBC upgrades CrowdStrike from hold to buy, citing attractive current valuation and projecting a non-GAAP EPS CAGR of 38.3% over FY26-29, indicating strong growth potential.
See More
SPX TECHNOLOGIES INC: BOFA GLOBAL RESEARCH UPGRADES TO BUY FROM NEUTRAL; INCREASES PRICE TARGET TO $280 FROM $240
- Global Research Initiative: A new initiative has been launched to buy from neutral sources, aiming to enhance global research capabilities.
- Price Increase Announcement: The objective price has been raised to $280 from the previous $240, reflecting the increased costs associated with the initiative.
See More
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
- Halozyme Financial Performance: Halozyme's Q3 revenue increased by 22% year-over-year to $354 million, with earnings per share (EPS) soaring 36% to $1.43, demonstrating its strong market position in drug delivery systems.
- Catalyst Growth Potential: Catalyst achieved a remarkable 249% revenue growth leading up to 2024, with Q3 revenue rising 24% year-over-year to $436.3 million and EPS climbing 45.9% to $1.27, reflecting strong demand in rare disease treatments.
- Competitive Advantage: Both companies maintain low debt levels, with Halozyme reducing its long-term debt from $1.5 billion to $800 million, while Catalyst has no debt, providing them with greater flexibility for acquisitions and R&D investments.
- Optimistic Industry Outlook: The biotech sector rebounded in 2025, with the SPDR S&P Biotech ETF rising 27%, indicating a resurgence in market demand for innovative drugs, while both Halozyme and Catalyst are valued below the sector average, suggesting significant future growth potential.
See More
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
- Biotech Recovery: In 2025, the SPDR S&P Biotech ETF surged 27%, nearly doubling the S&P 500's 16% gain, indicating a robust recovery in the biotech sector, supported by lower interest rates facilitating debt financing.
- Halozyme's Strong Growth: Halozyme Therapeutics saw its stock rise over 25% in the past year, with Q3 revenue increasing 22% year-over-year to $354 million and EPS jumping 36% to $1.43, showcasing its competitive edge in drug delivery systems.
- Catalyst's Profitability: Catalyst Pharmaceuticals reported a staggering 249% revenue growth from 2021 to 2024, with a 24% year-over-year increase in revenue to $436.3 million and a 45.9% rise in EPS to $1.27 this year, reflecting strong market demand in rare disease treatments.
- Optimistic Future Outlook: Halozyme forecasts annual revenue of $1.3 billion to $1.375 billion for 2026, representing 28% to 35% growth, while Catalyst anticipates revenue of $565 million to $585 million, nearly a 17% increase, indicating promising growth potential for both companies.
See More
Stocks Rebound as Trump Halts Greenland Tariffs, Future Deal Framework Announced
- Market Rebound: Stocks rebounded following President Trump's announcement to halt tariffs on Greenland, reflecting a renewed optimism in the market that could restore investor confidence and stimulate economic activity.
- Future Deal Framework: The “framework” mentioned by Trump suggests potential future trade agreements, which may positively influence trade relations between the U.S. and other nations, thereby impacting global market dynamics.
- New Buying Opportunities: Google and Eli Lilly emerge as leaders in new buying opportunities, indicating sustained investor confidence in the technology and pharmaceutical sectors, which could drive stock prices higher.
- Improved Market Sentiment: Trump's statement not only alleviates concerns over trade tensions but may also create more investment opportunities for other companies, enhancing overall economic growth expectations.
See More
Trump Halts Greenland Tariffs, Stocks Rebound
- Market Rebound: Stocks rebounded as President Trump announced he would not proceed with tariffs on Greenland, indicating investor optimism about a potential future trade deal, which could stimulate economic recovery.
- New Investment Opportunities: Google and Eli Lilly emerged as leading new buys, reflecting investor confidence in the technology and pharmaceutical sectors, potentially driving stock prices higher.
- Trade Framework Established: Trump's mention of a 'framework' for future agreements lays the groundwork for subsequent trade negotiations, which may improve trade relations between the U.S. and other countries.
- Investor Sentiment Improvement: With reduced uncertainty surrounding tariff policies, investor sentiment has improved, likely leading to increased capital inflows into the stock market, thereby enhancing overall market performance.
See More
